Cargando…

Effectiveness and Cost-Effectiveness of Inactivated Vaccine to Address COVID-19 Pandemic in China: Evidence From Randomized Control Trials and Real-World Studies

OBJECTIVE: This study aimed to determine the efficacy, effectiveness, and cost-effectiveness of inactivated COVID-19 vaccines (CoronaVac and BBIBP-CorV) in China using existing international clinical trials and real-world evidence. METHODS: Through a search of PubMed, Embase, Web of Science, and CNK...

Descripción completa

Detalles Bibliográficos
Autores principales: Fu, Yaqun, Zhao, Jingyu, Wei, Xia, Han, Peien, Yang, Li, Ren, Tao, Zhan, Siyan, Li, Liming
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9343737/
https://www.ncbi.nlm.nih.gov/pubmed/35928479
http://dx.doi.org/10.3389/fpubh.2022.917732
_version_ 1784761055724961792
author Fu, Yaqun
Zhao, Jingyu
Wei, Xia
Han, Peien
Yang, Li
Ren, Tao
Zhan, Siyan
Li, Liming
author_facet Fu, Yaqun
Zhao, Jingyu
Wei, Xia
Han, Peien
Yang, Li
Ren, Tao
Zhan, Siyan
Li, Liming
author_sort Fu, Yaqun
collection PubMed
description OBJECTIVE: This study aimed to determine the efficacy, effectiveness, and cost-effectiveness of inactivated COVID-19 vaccines (CoronaVac and BBIBP-CorV) in China using existing international clinical trials and real-world evidence. METHODS: Through a search of PubMed, Embase, Web of Science, and CNKI, studies investigating the effectiveness of inactivated COVID-19 vaccines were identified, and a meta-analysis was undertaken to synthesize the vaccine efficacy and effectiveness data. Moreover, a decision-analytic model was developed to estimate the cost-effectiveness of inactivated vaccines for combating the COVID-19 pandemic in the Chinese context from a societal perspective. Results of the meta-analysis, along with cost data from official websites and works of literature were used to populate the model. Sensitivity analysis was performed to test the robustness of the model results. RESULTS: A total of 24 studies were included in the meta-analysis. In comparison to no immunization, the effectiveness of inactivated vaccine against COVID-19 infection, hospitalization, ICU admission and death were 65.18% (95% CI 62.62, 67.75), 79.10% (95% CI 71.69, 86.51), 90.46% (95% CI 89.42, 91.50), and 86.69% (95% CI 85.68, 87.70); and the efficacy against COVID-19 infection and hospitalization were 70.56% (95% CI 57.87, 83.24) and 100% (95% CI 61.72, 100). Inactivated vaccine vaccination prevented more infections, hospitalizations, ICU admissions, and deaths with lower total costs, thus was cost-saving from a societal perspective in China. Base-case analysis results were robust in the one-way sensitivity analysis, and the percentage of ICU admission or death and direct medical cost ranked the top influential factors in our models. In the probabilistic sensitivity analysis, vaccination had a 100% probability of being cost-effective. CONCLUSION: Inactivated vaccine is effective in preventing COVID-19 infection, hospitalization, ICU admission and avoiding COVID-19 related death, and COVID-19 vaccination program is cost-saving from societal perspective in China.
format Online
Article
Text
id pubmed-9343737
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-93437372022-08-03 Effectiveness and Cost-Effectiveness of Inactivated Vaccine to Address COVID-19 Pandemic in China: Evidence From Randomized Control Trials and Real-World Studies Fu, Yaqun Zhao, Jingyu Wei, Xia Han, Peien Yang, Li Ren, Tao Zhan, Siyan Li, Liming Front Public Health Public Health OBJECTIVE: This study aimed to determine the efficacy, effectiveness, and cost-effectiveness of inactivated COVID-19 vaccines (CoronaVac and BBIBP-CorV) in China using existing international clinical trials and real-world evidence. METHODS: Through a search of PubMed, Embase, Web of Science, and CNKI, studies investigating the effectiveness of inactivated COVID-19 vaccines were identified, and a meta-analysis was undertaken to synthesize the vaccine efficacy and effectiveness data. Moreover, a decision-analytic model was developed to estimate the cost-effectiveness of inactivated vaccines for combating the COVID-19 pandemic in the Chinese context from a societal perspective. Results of the meta-analysis, along with cost data from official websites and works of literature were used to populate the model. Sensitivity analysis was performed to test the robustness of the model results. RESULTS: A total of 24 studies were included in the meta-analysis. In comparison to no immunization, the effectiveness of inactivated vaccine against COVID-19 infection, hospitalization, ICU admission and death were 65.18% (95% CI 62.62, 67.75), 79.10% (95% CI 71.69, 86.51), 90.46% (95% CI 89.42, 91.50), and 86.69% (95% CI 85.68, 87.70); and the efficacy against COVID-19 infection and hospitalization were 70.56% (95% CI 57.87, 83.24) and 100% (95% CI 61.72, 100). Inactivated vaccine vaccination prevented more infections, hospitalizations, ICU admissions, and deaths with lower total costs, thus was cost-saving from a societal perspective in China. Base-case analysis results were robust in the one-way sensitivity analysis, and the percentage of ICU admission or death and direct medical cost ranked the top influential factors in our models. In the probabilistic sensitivity analysis, vaccination had a 100% probability of being cost-effective. CONCLUSION: Inactivated vaccine is effective in preventing COVID-19 infection, hospitalization, ICU admission and avoiding COVID-19 related death, and COVID-19 vaccination program is cost-saving from societal perspective in China. Frontiers Media S.A. 2022-07-19 /pmc/articles/PMC9343737/ /pubmed/35928479 http://dx.doi.org/10.3389/fpubh.2022.917732 Text en Copyright © 2022 Fu, Zhao, Wei, Han, Yang, Ren, Zhan and Li. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Public Health
Fu, Yaqun
Zhao, Jingyu
Wei, Xia
Han, Peien
Yang, Li
Ren, Tao
Zhan, Siyan
Li, Liming
Effectiveness and Cost-Effectiveness of Inactivated Vaccine to Address COVID-19 Pandemic in China: Evidence From Randomized Control Trials and Real-World Studies
title Effectiveness and Cost-Effectiveness of Inactivated Vaccine to Address COVID-19 Pandemic in China: Evidence From Randomized Control Trials and Real-World Studies
title_full Effectiveness and Cost-Effectiveness of Inactivated Vaccine to Address COVID-19 Pandemic in China: Evidence From Randomized Control Trials and Real-World Studies
title_fullStr Effectiveness and Cost-Effectiveness of Inactivated Vaccine to Address COVID-19 Pandemic in China: Evidence From Randomized Control Trials and Real-World Studies
title_full_unstemmed Effectiveness and Cost-Effectiveness of Inactivated Vaccine to Address COVID-19 Pandemic in China: Evidence From Randomized Control Trials and Real-World Studies
title_short Effectiveness and Cost-Effectiveness of Inactivated Vaccine to Address COVID-19 Pandemic in China: Evidence From Randomized Control Trials and Real-World Studies
title_sort effectiveness and cost-effectiveness of inactivated vaccine to address covid-19 pandemic in china: evidence from randomized control trials and real-world studies
topic Public Health
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9343737/
https://www.ncbi.nlm.nih.gov/pubmed/35928479
http://dx.doi.org/10.3389/fpubh.2022.917732
work_keys_str_mv AT fuyaqun effectivenessandcosteffectivenessofinactivatedvaccinetoaddresscovid19pandemicinchinaevidencefromrandomizedcontroltrialsandrealworldstudies
AT zhaojingyu effectivenessandcosteffectivenessofinactivatedvaccinetoaddresscovid19pandemicinchinaevidencefromrandomizedcontroltrialsandrealworldstudies
AT weixia effectivenessandcosteffectivenessofinactivatedvaccinetoaddresscovid19pandemicinchinaevidencefromrandomizedcontroltrialsandrealworldstudies
AT hanpeien effectivenessandcosteffectivenessofinactivatedvaccinetoaddresscovid19pandemicinchinaevidencefromrandomizedcontroltrialsandrealworldstudies
AT yangli effectivenessandcosteffectivenessofinactivatedvaccinetoaddresscovid19pandemicinchinaevidencefromrandomizedcontroltrialsandrealworldstudies
AT rentao effectivenessandcosteffectivenessofinactivatedvaccinetoaddresscovid19pandemicinchinaevidencefromrandomizedcontroltrialsandrealworldstudies
AT zhansiyan effectivenessandcosteffectivenessofinactivatedvaccinetoaddresscovid19pandemicinchinaevidencefromrandomizedcontroltrialsandrealworldstudies
AT liliming effectivenessandcosteffectivenessofinactivatedvaccinetoaddresscovid19pandemicinchinaevidencefromrandomizedcontroltrialsandrealworldstudies